Skip to content
Dinoprostone
Cervidil, Prepidil (dinoprostone) is a small molecule pharmaceutical. Dinoprostone was first approved as Prostin e2 on 1982-01-01. It is used to treat fetal death, gestational trophoblastic disease, and uterine neoplasms in the USA. It is known to target solute carrier organic anion transporter family member 2A1, prostaglandin E2 receptor EP2 subtype, prostaglandin E2 receptor EP3 subtype, prostaglandin E2 receptor EP4 subtype, prostaglandin E2 receptor EP1 subtype, and solute carrier organic anion transporter family member 3A1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Cervidil, Prepidil (discontinued: Prostin e2)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dinoprostone
Tradename
Company
Number
Date
Products
CERVIDILFerring PharmaceuticalsN-020411 RX1995-03-30
1 products, RLD, RS
PREPIDILMylanN-019617 RX1992-12-09
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cervidilNew Drug Application2020-07-17
prepidilNew Drug Application2019-12-11
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
fetal deathHP_0003826D005313
gestational trophoblastic diseaseD031901O01.9
uterine neoplasmsEFO_0003859D014594C55
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
G02: Other gynecologicals in atc
G02A: Uterotonics
G02AD: Prostaglandins, oxytocics
G02AD02: Dinoprostone
HCPCS
No data
Clinical
Clinical Trials
335 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PainD010146EFO_0003843R5276813842
OsteoarthritisD010003EFO_0002506M15-M194165227
Knee osteoarthritisD020370EFO_0004616M172792423
Postoperative painD010149G89.18284519
Healthy volunteers/patients101314
Actinic keratosisD055623L57.0155112
Low back painD017116HP_0003419M54.5125210
PulpitisD011671EFO_1001139K04.043329
Ankle injuriesD016512S93.424128
Ankylosing spondylitisD013167EFO_0003898M45246
Show 50 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute painD059787R52166
InflammationD0072493115
Soft tissue injuriesD0176951214
Dental pinsD003772123
SciaticaD012585HP_0011868M54.3112
DysmenorrheaD004412HP_0100607N94.61112
Procedural painD00007381822
MyalgiaD063806HP_0003326M79.111
SunburnD013471EFO_0003958L5511
ColicD003085HP_0011848R10.8311
Show 16 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GoutD006073EFO_0004274M10112
Skin neoplasmsD012878EFO_0004198C4422
Gouty arthritisD01521011
Basal cell neoplasmsD01829511
NeoplasmsD009369C8011
Chronic periodontitisD055113EFO_0006343K05.3111
Chronic painD059350HP_001253211
Musculoskeletal painD05935211
Chronic kidney failureD007676EFO_0003884N18.611
ArthralgiaD018771HP_0002829M25.511
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50213
ArthritisD001168EFO_0005856M05-M14112
UveitisD014605EFO_1001231H20.9112
AgingD000375GO_0007568R41.8111
Carpal tunnel syndromeD002349EFO_0004143G56.011
Therapeutic equivalencyD01381011
Chronic renal insufficiencyD051436N1811
Hepatic insufficiencyD04855011
PharmacokineticsD01059911
Biological availabilityD00168211
Show 5 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CataractD002386EFO_0001059H26.922
Pathologic dilatationD00410822
KeratoconusD007640EFO_0004223H18.622
RegenerationD01203822
Diabetic retinopathyD003930EFO_000377022
HemostasisD00648711
Erectile dysfunctionD007172EFO_0004234F52.2111
HeadacheD006261HP_0002315R5111
TendinopathyD052256EFO_1001434M77.911
SynovitisD013585EFO_0008997M67.511
Show 24 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDINOPROSTONE
INNdinoprostone
Description
Prostaglandin E2 is prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. It has a role as an oxytocic, a human metabolite and a mouse metabolite. It is a conjugate acid of a prostaglandin E2(1-).
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O
Identifiers
PDB6AK3
CAS-ID363-24-6
RxCUI3478
ChEMBL IDCHEMBL548
ChEBI ID15551
PubChem CID5280360
DrugBankDB00917
UNII IDK7Q1JQR04M (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SLCO2A1
SLCO2A1
PTGER2
PTGER2
PTGER3
PTGER3
PTGER4
PTGER4
PTGER1
PTGER1
SLCO3A1
SLCO3A1
Organism
Homo sapiens
Gene name
SLCO2A1
Gene synonyms
OATP2A1, SLC21A2
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 2A1
Protein synonyms
matrin F/G 1, OATP2A1, PGT, PHOAR2, Prostaglandin transporter, SLC21A2, solute carrier family 21 (prostaglandin transporter), member 2, Solute carrier family 21 member 2
Uniprot ID
Mouse ortholog
Slco2a1 (24059)
solute carrier organic anion transporter family member 2A1 (Q9EPT5)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,420 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
72,409 adverse events reported
View more details